Scarica l'app Stockscreener
5.975
10.29%
-0.685
Pre-mercato:
6.05
0.075
+1.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVAX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.66
Aprire:
$6.605
Volume 24 ore:
19.95M
Relative Volume:
3.39
Capitalizzazione di mercato:
$1.04B
Reddito:
$847.25M
Utile/perdita netta:
$-284.86M
Rapporto P/E:
-2.6092
EPS:
-2.29
Flusso di cassa netto:
$-112.35M
1 W Prestazione:
-6.79%
1M Prestazione:
-11.48%
6M Prestazione:
-32.94%
1 anno Prestazione:
+33.67%
Intervallo 1D:
$5.80
$6.64
Intervallo di 1 settimana:
$5.80
$7.50
Portata 52W:
$5.01
$23.86
Novavax Inc Stock (NVAX) Company Profile
Nome
Novavax Inc
Settore
Industria
Telefono
240-268-2000
Indirizzo
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Confronta NVAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
5.975 | 1.04B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-28 | Iniziato | BTIG Research | Buy |
| 2024-07-30 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Reiterato | B. Riley Securities | Buy |
| 2022-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2022-12-02 | Iniziato | Jefferies | Hold |
| 2022-09-22 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Iniziato | BofA Securities | Underperform |
| 2022-02-23 | Reiterato | B. Riley Securities | Buy |
| 2022-02-22 | Ripresa | Jefferies | Buy |
| 2022-01-21 | Iniziato | Cowen | Outperform |
| 2021-05-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Iniziato | Jefferies | Buy |
| 2020-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Reiterato | B. Riley FBR | Buy |
| 2020-06-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Reiterato | B. Riley FBR | Buy |
| 2020-05-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-27 | Ripresa | B. Riley FBR | Buy |
| 2019-08-14 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-28 | Downgrade | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-11 | Iniziato | Oppenheimer | Outperform |
| 2018-11-26 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Aggiornamento | Seaport Global Securities | Neutral → Buy |
Mostra tutto
Novavax Inc Borsa (NVAX) Ultime notizie
JP Morgan Lowers Price Target for NVAX, Maintains Underweight Ra - GuruFocus
Novavax First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Benzinga Bulls And Bears: IBM, Novavax, Arm Holdings — And UK Trade Deal Boosts Markets - Benzinga
JP Morgan Lowers Price Target for NVAX, Maintains Underweight Rating | NVAX Stock News - GuruFocus
Why Novavax (NVAX) is a Top Momentum Stock for the Long-Term - Yahoo Finance
NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up - Yahoo Finance
Analysts Just Shipped An Incredible Upgrade To Their Novavax, Inc. (NASDAQ:NVAX) Estimates - Yahoo Finance
Novavax (NVAX) Faces Price Target Cut Amid Regulatory Concerns | NVAX Stock News - GuruFocus
Novavax: Q1 Earnings Snapshot - New Haven Register
Novavax Inc (NVAX) Q1 2025 Earnings Call Highlights: Revenue Surge Amid Strategic Partnerships ... - Yahoo Finance
Novavax Inc (NVAX) Q1 2025 Earnings Call Highlights: Revenue Sur - GuruFocus
Novavax Inc (NVAX) Q1 2025 Earnings Call Highlights: Revenue Surge Amid Strategic Partnerships ... By GuruFocus - Investing.com Canada
Decoding Novavax Inc (NVAX): A Strategic SWOT Insight - GuruFocus
Novavax (NVAX) Sets Sights on Profitability with Strategic Shifts - GuruFocus
Novavax (NVAX) Shares Surge After Upbeat Q1 Results and Raised R - GuruFocus
Health Care Stocks See Mixed Results In Market Movements - Finimize
Novavax projects $1.025B 2025 revenue framework with focus on partnerships - MSN
Novavax (NVAX) Eyes Resolution with FDA for Covid Vaccine Approval | NVAX Stock News - GuruFocus
Novavax says talks with FDA on COVID vaccine approval ongoing calming investor fears - Reuters
Why This Shrinking Covid-19 Vaccine Stock Jumped 30% - Barron's
COVID Vaccine Maker Novavax Stock Soars 16%Here's Why - Yahoo Finance
Novavax Q1 2025 slides: Revenue surges to $667M, company raises full-year guidance By Investing.com - Investing.com South Africa
Novavax (NVAX) Set to Release Q1 Earnings with Strong Revenue Gr - GuruFocus
FDA advisory panel to discuss makeup of updated COVID shots - Seeking Alpha
Novavax Hauls in $666M Q1 Windfall, Boosts FY25 Outlook - Yahoo Finance
Thursday's Top 5 Trending Stocks: What's Going On With D-Wave, Novavax, Carvana? - Benzinga
Novavax Stock Rallies On Upbeat Q1 Earnings, Revised Full-Year Revenue Forecast: Retail’s Elated By Stocktwits - Investing.com India
Earnings call transcript: Novavax Q1 2025 Surpasses Expectations with Strong Revenue Growth - Investing.com
Novavax Stock Rallies On Upbeat Q1 Earnings, Revised Full-Year Revenue Forecast: Retail’s Elated - MSN
Novavax earnings beat by $3.36, revenue topped estimates - Investing.com
Novavax stock soars 20% as Q1 results crush estimates By Investing.com - Investing.com Australia
Novavax swings to profit on lower expenses related to COVID shots - WHTC
Novavax rises after massive Q1 beat, guidance raise - MSN
Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
NVAX Earnings: Novavax Stock Soars 33% in Pre-Market on Explosive Q1 Profit - TipRanks
Novavax Q1 2025 slides: Revenue surges to $667M, company raises full-year guidance - Investing.com Australia
Novavax (NVAX) Reports Strong Q1 Earnings Boosted by APA Terminations - GuruFocus
Novavax (NVAX) Exceeds Q1 Expectations with Strong Earnings and Revenue - GuruFocus
Novavax (NVAX) Shares Surge After Upbeat Q1 Results and Raised Revenue Outlook - GuruFocus
Novavax Inc. Q1 2025 Earnings: EPS of $0.71, Revenue Surges to $667 Million, Exceeding Estimates - GuruFocus
Novavax stock rises after massive Q1 beat (NVAX:NASDAQ) - Seeking Alpha
Novavax jumps after vaccine maker swings to profit in first quarter - TradingView
Earnings snapshot: Novavax Q1 tops estimates; updates FY25 outlook - Seeking Alpha
Novavax Reports First Quarter 2025 Financial Results and Operational Highlights | NVAX Stock News - GuruFocus
Novavax Swings To Profit As COVID-19 Vaccine Costs Drop - Finimize
NOVAVAX INC SEC 10-Q Report - TradingView
Novavax Reports First Quarter 2025 Financial Results and Operational Highlights - PR Newswire
Novavax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Novavax to Report First Quarter 2025 Financial Results on May 8, 2025 - Longview News-Journal
US FDA advisers to discuss COVID-19 vaccine recommendations on May 22 - marketscreener.com
Novavax Inc Azioni (NVAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):